Urinary Tract Infection Companies

Disclaimer: List of key companies in no particular orderLatest Urinary tract infection Companies Update

• 
  Oct 2023: To counteract declining sales in oncology, Roche, a company based in Switzerland, has agreed to pay Roivant and Pfizer an initial sum of $7.1 billion for the rights to a novel medication for inflammatory bowel disease. Almost 8 million people globally have been diagnosed with inflammatory bowel disease, and 80% of those cases do not result in a long-lasting remission, according to Roche. Roche said that it would acquire Telavant Holdings, a company in which Pfizer and Roivant have invested the rights to research, development, and commercialization of the investigational medication known as RVT-3101 in the US and Japan. Thomas Schinecker, the new CEO of the Swiss pharmaceutical company, is eager to repair Roche's damaged reputation in drug development following significant late-stage trial failures in cancer immunotherapy and Alzheimer's disease.

• 
  May 2023: Together with Square, Cardinal Health, a manufacturer and seller of medical and laboratory supplies, offers independent pharmacy payment options. Through this partnership, independent pharmacists can use integrated software solutions for their business, improve operational efficiency, and stay current with client payment preferences. Independent pharmacies can provide their consumers with flexible payment alternatives like text-to-pay, Apply Pay, and Google Pay, thanks to this agreement, announced on May 31. Square Terminal hardware powers the in-store payment solution, which enables pharmacies to offer flexible patient payment options. Pharmacy Marketing Advantage Commerce, an online retailer, uses Square's Web Payments SDK to facilitate online sales.

• Pfizer Inc.


• Teva Pharmaceuticals


• Novo Nordisk A/S


• GlaxoSmithKline plc


• Bayer AG


• Novartis Ag


• Cipla Inc.


• Merck & Co. Inc.


• Eli Lily Company


• Allergan